NCT06860594View on ClinicalTrials.gov

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-MutantRecurrent Astrocytoma, IDH-MutantRecurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

PROCEDURE

Computed Tomography

Undergo CT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Triapine

Given PO

Trial Locations (14)

23298

RECRUITING

VCU Massey Comprehensive Cancer Center, Richmond

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

40536

RECRUITING

University of Kentucky/Markey Cancer Center, Lexington

53718

RECRUITING

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison

53792

RECRUITING

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

60611

RECRUITING

Northwestern University, Chicago

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

92093

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

92612

RECRUITING

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

06520

RECRUITING

Yale University, New Haven

06611

RECRUITING

Smilow Cancer Hospital Care Center-Trumbull, Trumbull

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH